三葉草生物-B(02197.HK)獲得國光生技四價季節性流感疫苗內地獨家商業化授權
三葉草生物-B(02197.HK)公布,其與國光生技達成AdimFlu-S(QIS)在中國分銷的獨家協議,該款疫苗是內地目前唯一獲批用於三歲及以上人群的進口四價季節性流感疫苗。該獨家協議還授權三葉草生物獲得註冊部門批准後,在孟加拉國、巴西和菲律賓商業化AdimFlu-S(QIS),並有望與國光生技合作開發其他候選疫苗,包括下一代流感疫苗。
公司指出,在內地不斷增長且穩定的流感疫苗市場中,有關交易預計將在2023年對公司的財務狀況帶來增量,並在2024年及以後創造具有意義的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.